A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 360 (planned)
- Started
- Feb 12, 2025
- Main results expected
- Sep 5, 2026
- Fully finished
- Dec 9, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participnats with Adverse Events (AEs)
Measured over: Up to 100 days following discontinuation of dosing
Number of participants with Serious AEs (SAEs)
Measured over: Up to 100 days following discontinuation of dosing
Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
Measured over: Up to 28 days after the first treatment of study intervention
Number of participants with AEs leading to discontinuation
Measured over: Up to 100 days following discontinuation of dosing
Number of deaths
Measured over: Up to 100 days following discontinuation of dosing
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06730750 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC